With a clear focus on reduction of the information arbitrage, Heckyl has built an alternative data platform FiND which collects and organizes macro, micro, and financial data to provide unique insights into pharmaceutical sector.
In our view, trading opportunities can be spotted in the stock market by discovery and analysis of vast amount of alternative data available on the web. One such data set is clinical trial study results for pharmaceutical companies.
Clinical trials are research studies that explore whether a drug or device is safe and effective for humans. The pharmaceutical products go through three phases of clinical trials followed by a regulatory approval process. After completing all three phases and the approval process, the company can start monetizing the drug or device.
The drugmakers report the progress of ongoing clinical trials for each phase from time to time. The result of late study trials (phase 2 and 3) can provide the best idea about a drug’s chances of approval. A favorable result of late study trials can be seen as positive by the market and vice-versa.
To help traders/ investors, we have introduced Calendar which tracks release dates for clinical trial, drug approval, patent expiry, operating stats and industry events.
We present a case study on Clearside Biomedical, Inc., a late-stage biopharmaceutical company developing drug therapies to treat back-of-the-eye diseases.
On Mar. 5, 2018, Clearside announced positive topline results from its pivotal Phase 3 clinical trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis (Image 1).
(Image 1: News screen for Clearside)
Following the release of results for suprachoroidal CLS-TA phase 3 studies, the shares of Clearside rallied 32% on March 5 (Image 2).
(Image 2: Price and news summary chart for Clearside)
The release date for Clearside’ suprachoroidal CLS-TA phase 3 study was captured by FiND Calendar (Image 3). With the prior knowledge of release date for Clearside’s trial study result, one could have exploited this opportunity ahead of others.
(Image 3: Calendar screen for Clearside)
In this month, 31 companies are expected to release clinical trial study results for 38 drugs. Out of the total, phase 2 and phase 3 study results are expected from 14 companies. Moreover, 15 companies are expecting regulatory approval (PDUFA/ PDUFA priority review) for one drug each.
We highlight 7 such companies which are expected to release updates on Phase 2, Phase 3 and PDUFA priority review during the next week below.
- Eli Lilly
- Bristol-Myers Squibb
- Selecta Biosciences
- Eiger Biopharmaceuticals
- Galectin Therapeutics
- Merck & Co
Switzerland based Novartis is expected to release phase 3 clinical trial study result for Cosentyx (Image 4) on April 9.
(Image 4: Calendar Screen)
By keeping track of clinical trial study release dates in FiND Calendar, traders/ investors can spot new opportunities ahead of the market.
To know more about FiND, email us at firstname.lastname@example.org